The Therapeutic Potential of Mangosteen Pericarp as an Adjunctive Therapy for Bipolar Disorder and Schizophrenia

Melanie M Ashton; Olivia M Dean; Adam J Walker; Chiara C Bortolasci; Chee H Ng; Malcolm Hopwood; Brian H Harvey; Marisa Möller; John J McGrath; Wolfgang Marx; Alyna Turner; Seetal Dodd; James G Scott; Jon-Paul Khoo; Ken Walder; Jerome Sarris; Michael Berk

doi:10.3389/fpsyt.2019.00115

The Therapeutic Potential of Mangosteen Pericarp as an Adjunctive Therapy for Bipolar Disorder and Schizophrenia

Melanie M Ashton, Olivia M Dean, Adam J Walker, Chiara C Bortolasci, Chee H Ng, Malcolm Hopwood, Brian H Harvey, Marisa Möller, John J McGrath, Wolfgang Marx, Alyna Turner, Seetal Dodd, James G Scott, Jon-Paul Khoo, Ken Walder, Jerome Sarris, Michael Berk

Research output: Contribution to journal › Review article › Research › peer-review

18 Citations (Scopus)

129 Downloads (Pure)

Abstract

New treatments are urgently needed for serious mental illnesses including bipolar disorder and schizophrenia. This review proposes that Garcinia mangostana Linn. (mangosteen) pericarp is a possible adjunctive therapeutic agent for these disorders. Research to date demonstrates that neurobiological properties of the mangosteen pericarp are well aligned with the current understanding of the pathophysiology of bipolar disorder and schizophrenia. Mangosteen pericarp has antioxidant, putative neuroprotective, anti-inflammatory, and putative mitochondrial enhancing properties, with animal studies demonstrating favorable pharmacotherapeutic benefits with respect to these disorders. This review summarizes evidence of its properties and supports the case for future studies to assess the utility of mangosteen pericarp as an adjunctive treatment option for mood and psychotic disorders.

Original language	English
Article number	115
Number of pages	17
Journal	Frontiers in Psychiatry
Volume	10
DOIs	https://doi.org/10.3389/fpsyt.2019.00115
Publication status	Published - 13 Mar 2019
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3389/fpsyt.2019.00115Licence: CC BY

The Therapeutic Potential of Mangosteen Pericarp as an Adjunctive Therapy for Bipolar Disorder and SchizophreniaFinal published version, 1.39 MBLicence: CC BY

Cite this

Ashton, M. M., Dean, O. M., Walker, A. J., Bortolasci, C. C., Ng, C. H., Hopwood, M., Harvey, B. H., Möller, M., McGrath, J. J., Marx, W., Turner, A., Dodd, S., Scott, J. G., Khoo, J.-P., Walder, K., Sarris, J., & Berk, M. (2019). The Therapeutic Potential of Mangosteen Pericarp as an Adjunctive Therapy for Bipolar Disorder and Schizophrenia. Frontiers in Psychiatry, 10, Article 115. https://doi.org/10.3389/fpsyt.2019.00115

@article{e0446dec55074848a32295dab9631c41,

title = "The Therapeutic Potential of Mangosteen Pericarp as an Adjunctive Therapy for Bipolar Disorder and Schizophrenia",

abstract = "New treatments are urgently needed for serious mental illnesses including bipolar disorder and schizophrenia. This review proposes that Garcinia mangostana Linn. (mangosteen) pericarp is a possible adjunctive therapeutic agent for these disorders. Research to date demonstrates that neurobiological properties of the mangosteen pericarp are well aligned with the current understanding of the pathophysiology of bipolar disorder and schizophrenia. Mangosteen pericarp has antioxidant, putative neuroprotective, anti-inflammatory, and putative mitochondrial enhancing properties, with animal studies demonstrating favorable pharmacotherapeutic benefits with respect to these disorders. This review summarizes evidence of its properties and supports the case for future studies to assess the utility of mangosteen pericarp as an adjunctive treatment option for mood and psychotic disorders.",

author = "Ashton, {Melanie M} and Dean, {Olivia M} and Walker, {Adam J} and Bortolasci, {Chiara C} and Ng, {Chee H} and Malcolm Hopwood and Harvey, {Brian H} and Marisa M{\"o}ller and McGrath, {John J} and Wolfgang Marx and Alyna Turner and Seetal Dodd and Scott, {James G} and Jon-Paul Khoo and Ken Walder and Jerome Sarris and Michael Berk",

year = "2019",

month = mar,

day = "13",

doi = "10.3389/fpsyt.2019.00115",

language = "English",

volume = "10",

journal = "Frontiers in Psychiatry",

issn = "1664-0640",

publisher = "Frontiers Media S.A.",

}

Ashton, MM, Dean, OM, Walker, AJ, Bortolasci, CC, Ng, CH, Hopwood, M, Harvey, BH, Möller, M, McGrath, JJ, Marx, W, Turner, A, Dodd, S, Scott, JG, Khoo, J-P, Walder, K, Sarris, J & Berk, M 2019, 'The Therapeutic Potential of Mangosteen Pericarp as an Adjunctive Therapy for Bipolar Disorder and Schizophrenia', Frontiers in Psychiatry, vol. 10, 115. https://doi.org/10.3389/fpsyt.2019.00115

TY - JOUR

T1 - The Therapeutic Potential of Mangosteen Pericarp as an Adjunctive Therapy for Bipolar Disorder and Schizophrenia

AU - Ashton, Melanie M

AU - Dean, Olivia M

AU - Walker, Adam J

AU - Bortolasci, Chiara C

AU - Ng, Chee H

AU - Hopwood, Malcolm

AU - Harvey, Brian H

AU - Möller, Marisa

AU - McGrath, John J

AU - Marx, Wolfgang

AU - Turner, Alyna

AU - Dodd, Seetal

AU - Scott, James G

AU - Khoo, Jon-Paul

AU - Walder, Ken

AU - Sarris, Jerome

AU - Berk, Michael

PY - 2019/3/13

Y1 - 2019/3/13

N2 - New treatments are urgently needed for serious mental illnesses including bipolar disorder and schizophrenia. This review proposes that Garcinia mangostana Linn. (mangosteen) pericarp is a possible adjunctive therapeutic agent for these disorders. Research to date demonstrates that neurobiological properties of the mangosteen pericarp are well aligned with the current understanding of the pathophysiology of bipolar disorder and schizophrenia. Mangosteen pericarp has antioxidant, putative neuroprotective, anti-inflammatory, and putative mitochondrial enhancing properties, with animal studies demonstrating favorable pharmacotherapeutic benefits with respect to these disorders. This review summarizes evidence of its properties and supports the case for future studies to assess the utility of mangosteen pericarp as an adjunctive treatment option for mood and psychotic disorders.

AB - New treatments are urgently needed for serious mental illnesses including bipolar disorder and schizophrenia. This review proposes that Garcinia mangostana Linn. (mangosteen) pericarp is a possible adjunctive therapeutic agent for these disorders. Research to date demonstrates that neurobiological properties of the mangosteen pericarp are well aligned with the current understanding of the pathophysiology of bipolar disorder and schizophrenia. Mangosteen pericarp has antioxidant, putative neuroprotective, anti-inflammatory, and putative mitochondrial enhancing properties, with animal studies demonstrating favorable pharmacotherapeutic benefits with respect to these disorders. This review summarizes evidence of its properties and supports the case for future studies to assess the utility of mangosteen pericarp as an adjunctive treatment option for mood and psychotic disorders.

UR - http://www.scopus.com/inward/record.url?scp=85066445254&partnerID=8YFLogxK

U2 - 10.3389/fpsyt.2019.00115

DO - 10.3389/fpsyt.2019.00115

M3 - Review article

C2 - 30918489

SN - 1664-0640

VL - 10

JO - Frontiers in Psychiatry

JF - Frontiers in Psychiatry

M1 - 115

ER -

The Therapeutic Potential of Mangosteen Pericarp as an Adjunctive Therapy for Bipolar Disorder and Schizophrenia

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Nutrition Research for Mental Health, Cognition and Eating Disorders

Cite this

The Therapeutic Potential of Mangosteen Pericarp as an Adjunctive Therapy for Bipolar Disorder and Schizophrenia

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Related Projects

Nutrition Research for Mental Health, Cognition and Eating Disorders

Cite this